Monopar Therapeutics CEO exercises options, sells shares
The exercised options had expiration dates of August 8, 2028, and February 1, 2032.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Monopar Therapeutics Chief Executive Officer Chandler Robinson exercised options for 14,056 common shares at $30 per share and 15,000 at $14 per share on September 24, 2026. He also sold 10,450, 9,638, 8,368 and 600 shares at weighted average prices of $87.15, $87.96, $88.97 and $89.79 per share, respectively, on that date. The transactions were effected under a Rule 10b5-1 Plan executed June 25, 2026. The report also lists 62,815 shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Insider Trade Summary 10b5-1
Exercise and Sale: 29,056 shares ($1.93M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Robinson Chandler
Role
Chief Executive Officer
Sold
29,056 shs ($2.56M)
Approx. gross sale proceeds
$2.56M
Approx. exercise cost
$632K
Approx. pre-tax spread
$1.93M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 14,056 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F3 | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 14,056 | $30.00 | $422K |
| Exercise | Common Stock F1 | 15,000 | $14.00 | $210K |
| Sale | Common Stock F1, F5 | 10,450 | $87.15 | $911K |
| Sale | Common Stock F1, F6 | 9,638 | $87.96 | $848K |
| Sale | Common Stock F1, F7 | 8,368 | $88.97 | $745K |
| Sale | Common Stock F1, F8 | 600 | $89.79 | $54K |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 42,248 contracts (Direct);
Common Stock — 99,267 shares (Direct);
Common Stock — 62,815 shares (Indirect, See Footnote)
Footnotes (8)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.
- F2. On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3. On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
- F4. Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.
Key Figures
Option exercise: 14,056 shares; $30 per share
Option exercise: 15,000 shares; $14 per share
Shares sold and weighted average price: 10,450 shares; $87.15 per share
+4 more
7 metrics
Option exercise
14,056 shares; $30 per share
Exercised September 24, 2026; option expiration August 8, 2028.
Option exercise
15,000 shares; $14 per share
Exercised September 24, 2026; option expiration February 1, 2032.
Shares sold and weighted average price
10,450 shares; $87.15 per share
September 24, 2026.
Shares sold and weighted average price
9,638 shares; $87.96 per share
September 24, 2026.
Shares sold and weighted average price
8,368 shares; $88.97 per share
September 24, 2026.
Shares sold and weighted average price
600 shares; $89.79 per share
September 24, 2026.
Shares held by trust
62,815 shares
Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Key Terms
Rule 10b5-1 Plan, weighted average price, vesting commencement date
3 terms
Rule 10b5-1 Plan regulatory
"effected pursuant to a Rule 10b5-1 Plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting commencement date financial
"vesting commencement date of October 1, 2018"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did MNPR CEO Chandler Robinson exercise?
Chandler Robinson exercised options for 14,056 shares at $30 per share and 15,000 shares at $14 per share on September 24, 2026.
When do the exercised MNPR options expire?
The options associated with the 14,056-share exercise expire on August 8, 2028; those associated with the 15,000-share exercise expire on February 1, 2032.
AI-generated analysis. How Rhea-AI works. Not financial advice.
